ArticleFrontiers in bioengineering and biotechnology2025
A novel PolyAr87-based cell transfection protocol for nanobody expression optimized via a targeted design of transfection approach.
Article in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Transfection is a fundamental technique for introducing foreign nucleic acids into eukaryotic cells, widely used in biotechnology for recombinant protein expression. Nanobodies fused to enzymes are key reagents in the development of diagnostic tests such as ELISA. Here, we optimized a novel, low-cost, ready-to-use linear polyethyleneimine (PEI)-based transfection reagent, PolyAr87, for the efficient delivery of a plasmid encoding a nanobody-HRP fusion protein into HEK293T cells. Results: When compared with other commonly used transfection reagents-including branched and linear PEI and FuGene® 6-PolyAr87 showed superior performance over PEI powders and comparable efficacy to FuGene® 6 at a substantially lower cost. Then, using a Design of Experiments (DoE) approach, specifically the Design of Transfection (DoT) model, we applied a two-phase optimization strategy comprising a Full Factorial Design (FFD) and a Box-Behnken Design (BBD) to identify and fine-tune key factors affecting transfection efficiency. PolyAr87 concentration and DNA concentration were found to significantly influence outcomes, with optimal efficiency achieved at 1.75 μg/mL of DNA and 5.0 μg/ mL of PolyAr87. Discussion: Model validation demonstrated strong predictive power and reproducibility. These findings confirm both the effectiveness of PolyAr87 as a cost-efficient transfection reagent and the utility of DoT-based optimization for enhancing gene delivery protocols in mammalian cell systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.